CHF

Mammalian organs vary widely in regenerative capacity. Poorly regenerative organs, such as the heart are particularly vulnerable to organ failure. Once established, heart failure commonly results in mortality. The Hippo pathway, a kinase cascade that prevents adult cardiomyocyte proliferation and regeneration, is upregulated in human heart failure. Here we show that deletion of the Hippo pathway component Salvador (Salv) in mouse hearts with established ischaemic heart failure after myocardial infarction induces a reparative genetic program with increased scar border vascularity, reduced fibrosis, and recovery of pumping function compared with controls...

No abstract text is available yet for this article.

No abstract text is available yet for this article.

BACKGROUND: Cheyne-Stokes respiration (CSR) is common in patients with congestive heart failure (CHF) and is associated with poor prognosis. The aim of this study was to analyse the characteristics of CSR in patients with varying degrees of impaired left ventricular ejection fraction (LVEF). METHODS: A total of 104 patients with CSR (apnea-hypopnea index [AHI]15/h) and exertional dyspnea were divided into FIVE groups according to their LVEF (<20% upto 50%). A subgroup of 22 patients was studied twice: 15 in whom LVEF improved between studies and 7 in whom LVEF deteriorated...

IMPORTANCE: The β-blockers carvedilol and metoprolol succinate both reduce mortality in patients with heart failure (HF), but the comparative clinical effectiveness of these drugs is unknown. OBJECTIVE: To investigate whether carvedilol is associated with improved survival compared with metoprolol succinate. DESIGN, SETTING, AND PARTICIPANTS: Cohort study of patients with incident HF with reduced left ventricular ejection fraction (LVEF) (≤40%) who received carvedilol (n = 6026) or metoprolol succinate (n = 5638) using data from a Danish national HF registry linked with health care and administrative databases...

BACKGROUND: Loop diuretics are an essential component of therapy for patients with acute decompensated heart failure, but there are few prospective data to guide their use. METHODS: In a prospective, double-blind, randomized trial, we assigned 308 patients with acute decompensated heart failure to receive furosemide administered intravenously by means of either a bolus every 12 hours or continuous infusion and at either a low dose (equivalent to the patient's previous oral dose) or a high dose (2...